World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
60727
World Ranking
5253
National Ranking
2834

Overview

Robert P. Giugliano is affiliated with Brigham and Women's Hospital in the United States. Their research primarily focuses on medicine, with a significant concentration in cardiology and cardiovascular medicine. Their work spans multiple subfields, including cardiology and cardiovascular medicine, surgery, economics and econometrics, endocrinology, diabetes and metabolism, and internal medicine.

Their scholarly output centers around several key topics, notably lipoproteins and cardiovascular health, atrial fibrillation management and outcomes, antiplatelet therapy and cardiovascular diseases, health systems, economic evaluations, and quality of life, cardiac arrhythmias and treatments, venous thromboembolism diagnosis and management, as well as diabetes, cardiovascular risks, and lipoproteins.

Giugliano has published extensively in a number of prestigious journals. Frequent publication venues include:

  • Circulation
  • Journal of the American College of Cardiology
  • European Heart Journal
  • JAMA Cardiology
  • American Heart Journal

Frequent coauthors reflect ongoing collaborations within the cardiovascular research community. These include:

  • Marc S. Sabatine
  • Christian T. Ruff
  • Sabina A. Murphy
  • Eugene Braunwald
  • Elliott M. Antman

Among recent publications, the following papers are notable for their relevance and citation impact:

  • Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease, 2022, Circulation
  • Lipoprotein(a) and its Significance in Cardiovascular Disease, 2022, JAMA Cardiology
  • Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials, 2020, The Lancet
  • Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis, 2021, JAMA Cardiology
  • Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis, 2020, Stroke

Giugliano's research addresses critical issues in lipid management, cardiovascular disease prevention, and stroke risk reduction. Their contributions span clinical trials, systematic reviews, and meta-analyses, advancing knowledge in therapies targeting lipoprotein levels and cardiovascular outcomes.

Best Publications

  • Edoxaban versus warfarin in patients with atrial fibrillation

    Robert P. Giugliano;Christian T. Ruff;Eugene Braunwald;Sabina A. Murphy

  • Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

    Marc S. Sabatine;Robert P. Giugliano;Anthony C. Keech;Narimon Honarpour

  • Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

    Christian T Ruff;Robert P Giugliano;Eugene Braunwald;Elaine B Hoffman

  • TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy.

    David A. Morrow;Elliott M. Antman;Andrew Charlesworth;Richard Cairns

  • Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

    Michael G. Silverman;Brian A. Ference;Kyungah Im;Stephen D. Wiviott

  • Abciximab Facilitates the Rate and Extent of Thrombolysis Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial

    Elliott M. Antman;Robert P. Giugliano;C. Michael Gibson;Carolyn H. McCabe

  • Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes

    Marc S. Sabatine;David A. Morrow;Robert P. Giugliano;Paul B.J. Burton

  • Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.

    Michelle L. O’Donoghue;Sergio Fazio;Robert P. Giugliano;Erik S.G. Stroes

  • Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

    Marc P. Bonaca;Patrice Nault;Robert P. Giugliano;Anthony C. Keech

  • Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes

    Brian A. Ference;Jennifer G. Robinson;Robert D. Brook;Alberico L. Catapano

  • Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

    Christian T. Ruff;Robert P. Giugliano;Elliott M. Antman;Sharon E. Crugnale

  • Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

    Robert P. Giugliano;Terje R. Pedersen;Jeong Gun Park;Gaetano M. De Ferrari

  • Early versus delayed, provisional eptifibatide in acute coronary syndromes.

    Robert P. Giugliano;Jennifer A. White;Christoph Bode;Paul W. Armstrong

  • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

    Robert P Giugliano;Nihar R Desai;Payal Kohli;William J Rogers

  • TNK–Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction Results of the TIMI 10B Trial

    Christopher P. Cannon;C. Michael Gibson;Carolyn H. McCabe;A. A. Jennifer Adgey

  • Cognitive Function in a Randomized Trial of Evolocumab

    Robert P. Giugliano;François Mach;Kenton Zavitz;Christopher Kurtz

  • Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

    Marc S Sabatine;Lawrence A Leiter;Stephen D Wiviott;Robert P Giugliano

  • Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

    M.S. Sabatine;R.P. Giugliano;S.D. Wiviott

  • Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

    Christian T Ruff;Robert P Giugliano;Eugene Braunwald;David A Morrow

  • Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.

    Christopher P. Cannon;Robert P. Giugliano;Michael A. Blazing;Robert A. Harrington

Frequent Co-Authors

Eugene Braunwald
Eugene Braunwald Harvard Medical School
Elliott M. Antman
Elliott M. Antman Brigham and Women's Hospital
Sabina A. Murphy
Sabina A. Murphy Brigham and Women's Hospital
Marc S. Sabatine
Marc S. Sabatine Brigham and Women's Hospital
Christopher P. Cannon
Christopher P. Cannon Brigham and Women's Hospital
C. Michael Gibson
C. Michael Gibson Beth Israel Deaconess Medical Center
David A. Morrow
David A. Morrow Brigham and Women's Hospital
Stephen D. Wiviott
Stephen D. Wiviott Brigham and Women's Hospital
Robert A. Harrington
Robert A. Harrington Cornell University
Anthony C. Keech
Anthony C. Keech University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens the door to a variety of rewarding careers beyond the traditional MD route. Busy professionals or those looking for alternative entry points might consider fast track LPN programs online. These allow students to quickly become Licensed Practical Nurses, gaining essential hands-on experience and entering the workforce sooner.

Mental health is a growing field with a strong need for qualified professionals. For those interested in advanced nursing roles, fast track mental health nursing programs let you specialize as a Psychiatric Mental Health Nurse Practitioner much faster than traditional options.

The healthcare sector also needs strong leadership and management. If you’re considering the business side of healthcare, health administration degrees online deliver the flexibility to study while working. Competitive tuition rates make these pathways realistic for more students. For advanced leadership roles, an affordable mha online helps you prepare for executive positions without a hefty financial burden.

These diverse degrees and career paths offer flexibility, affordability, and the ability to make a real impact in healthcare—both clinical and administrative.

Best Scientists Citing Robert P. Giugliano

Trending Scientists

Recently Published Articles